Want to see HK:6669 full AI Analyst Report?
Top Page
Acotec Scientific Holdings Limited
(6669)
Select Model
Select Model
Rating:63Neutral
Price Target:
HK$6.50
▼(-54.10% Downside)
Action:Reiterated
Date:08/06/26
The score is driven primarily by improved financial performance (stronger margins, higher earnings, and much better free cash flow with modest leverage), tempered by a weak technical setup (price below key moving averages and negative MACD). Valuation is reasonable at ~16.9x earnings but lacks dividend support due to missing yield data.
Positive Factors
Improved profitability
The move to an 18.5% net margin from 9.8% and a roughly 72% gross margin indicates materially stronger earnings economics in 2025. If retained, this profitability provides more internal funding for product development, hospital coverage, and commercialization while improving resilience.
Negative Factors
Historical earnings volatility
Past losses and the sharp 2023 earnings decline show that profitability has not yet been consistently dependable across business conditions. This history makes the recent margin recovery less proven and raises the risk that earnings could weaken again if operating or market conditions become less supportive.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved profitability
The move to an 18.5% net margin from 9.8% and a roughly 72% gross margin indicates materially stronger earnings economics in 2025. If retained, this profitability provides more internal funding for product development, hospital coverage, and commercialization while improving resilience.
Read all positive factors
Acotec Scientific Holdings Limited (6669) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.88B
Dividend YieldN/A
Average Volume (3M)444.76K
Price to Earnings (P/E)―
Beta (1Y)1.13
Revenue Growth20.65%
EPS Growth127.07%
CountryHK
Employees955
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.16
Shares Outstanding313,389,160
10 Day Avg. Volume458,156
30 Day Avg. Volume444,756
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)2.48
Price to Sales (P/S)5.68
P/FCF Ratio25.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.56
Revenue Forecast (FY)HK$739.92M
Acotec Scientific Holdings Limited Business Overview & Revenue Model
Company Description
Acotec Scientific Holdings Limited is a medical technology firm specializing in the research and development of percutaneous transluminal angioplasty (PTA) and drug-coated balloon devices. These innovative products are designed to address various ...
How the Company Makes Money
Acotec Scientific Holdings Limited makes money primarily by selling interventional medical devices used in vascular procedures. Its revenue model is predominantly product-sales driven: the company generates income when hospitals and medical instit...
Acotec Scientific Holdings Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 625.00M | 644.63M | 533.99M | 473.85M | 395.55M | 303.81M |
| Gross Profit | 448.99M | 476.31M | 402.72M | 377.42M | 336.35M | 265.94M |
| EBITDA | -26.49M | 129.65M | 112.48M | 70.54M | 91.17M | -51.02M |
| Net Income | -50.23M | 119.18M | 52.28M | 14.49M | 70.14M | -79.08M |
Balance Sheet | ||||||
| Total Assets | 1.78B | 1.87B | 1.66B | 1.61B | 1.41B | 1.31B |
| Cash, Cash Equivalents and Short-Term Investments | 806.80M | 948.37M | 809.57M | 879.21M | 986.46M | 1.14B |
| Total Debt | 193.70M | 244.49M | 202.92M | 234.00M | 47.78M | 24.57M |
| Total Liabilities | 387.59M | 392.18M | 312.76M | 314.53M | 134.46M | 100.17M |
| Stockholders Equity | 1.40B | 1.48B | 1.35B | 1.30B | 1.28B | 1.21B |
Cash Flow | ||||||
| Free Cash Flow | -2.20M | 145.46M | 5.31M | -92.54M | -115.45M | -31.72M |
| Operating Cash Flow | 8.41M | 167.32M | 102.79M | -12.88M | -68.75M | -10.48M |
| Investing Cash Flow | -253.82M | -527.16M | 45.02M | -319.22M | -49.17M | -20.48M |
| Financing Cash Flow | -3.00M | 24.79M | -35.24M | -23.21M | -32.87M | 1.02B |
Acotec Scientific Holdings Limited Technical Analysis
Negative
14.16
Price Trends
7.38
Negative
8.28
Negative
10.67
Negative
Market Momentum
-0.35
Positive
32.00
Neutral
11.16
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6669, the sentiment is Negative. The current price of 14.16 is above the 20-day moving average (MA) of 6.48, above the 50-day MA of 7.38, and above the 200-day MA of 10.67, indicating a bearish trend. The MACD of -0.35 indicates Positive momentum. The RSI at 32.00 is Neutral, neither overbought nor oversold. The STOCH value of 11.16 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6669.
Acotec Scientific Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$5.44B | 12.34 | 13.24% | 2.41% | 16.15% | 31.89% | |
67 Neutral | HK$4.71B | 21.48 | 10.38% | 1.74% | 3.83% | -27.04% | |
63 Neutral | HK$1.88B | -30.91 | -3.50% | ― | 20.65% | 127.07% | |
59 Neutral | HK$5.94B | 90.22 | 1.72% | ― | 0.75% | -20.22% | |
59 Neutral | HK$2.81B | 27.76 | 4.06% | ― | 94.80% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | HK$11.65B | 31.24 | 6.07% | 0.06% | -3.62% | ― |
* Healthcare Sector Average
HK:6669
Acotec Scientific Holdings Limited
5.78
-9.37
-61.86%
HK:0853
MicroPort Scientific
6.08
-7.84
-56.33%
HK:1302
LifeTech Scientific Corporation
1.35
-0.54
-28.57%
HK:1789
AK Medical Holdings Ltd.
4.91
-0.73
-13.03%
HK:2172
MicroPort NeuroTech Limited
8.06
-4.96
-38.11%
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
6.66
-1.97
-22.83%
Acotec Scientific Holdings Limited Corporate Events
Acotec Swings to Loss on R&D Surge and U.S. Trial Impairment
Aug 31, 2026
Acotec Scientific Holdings Limited, a medical device maker specializing in vascular intervention products like drug-coated balloons, reported mixed interim results for the six months ended June 30, 2026. The company continues to invest heavily in ...
Acotec Scientific Sets Board Meeting to Review Interim Results and Consider Dividend
Aug 19, 2026
Acotec Scientific Holdings Limited has scheduled a board meeting for August 31, 2026 to review and approve the unaudited interim results for the six months ended June 30, 2026. The board will also consider the possible declaration of an interim di...
Acotec Issues Profit Warning After Halting U.S. Clinical Program
Aug 12, 2026
Acotec Scientific Holdings Limited has warned that it expects to swing to a net loss of no more than RMB80.9 million for the six months ended June 30, 2026, compared with a net profit of about RMB88.6 million a year earlier. The deterioration is m...
Acotec Shareholders Approve All Resolutions at 2026 AGM
Jun 16, 2026
Acotec Scientific Holdings Limited reported that all resolutions proposed at its annual general meeting held in Beijing on June 16, 2026, were approved by shareholders via poll. Shareholders adopted the audited financial statements for the year en...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.